Agios Pharmaceuticals Inc(AGIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:00 PM ET (Korea 10/28 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -7.01 | Insider Own | 2.42% | Shs Outstand | 59.6M | Perf Week | 3.79% |
| Market Cap | 2.27B | Forward P/E | - | EPS next Y | 34.68% | Insider Trans | -2.43% | Shs Float | 58.3M | Perf Month | 13.79% |
| Enterprise Value | 1.68B | PEG | - | EPS next Q | -1.25 | Inst Own | 116.69% | Short Float | 11.84% | Perf Quarter | 8.63% |
| Income | -0.41B | P/S | 23.09 | EPS this Y | 19.04% | Inst Trans | 7.21% | Short Ratio | 6.29 | Perf Half Y | 53.35% |
| Sales | 0.10B | P/B | 2.21 | EPS next 5Y | 37.17% | ROA | -31.89% | Short Interest | 6.89M | Perf YTD | 39.71% |
| Book/sh | 17.21 | P/C | 3.68 | EPS past 3/5Y | -18.95% -8.46% | ROE | -34.34% | 52W High | -17.33% ($46.00) | Perf Year | -11.72% |
| Cash/sh | 10.34 | P/FCF | - | Sales past 3/5Y | 55.97% - | ROIC | -39.62% | 52W Low | 71% ($22.24) | Perf 3Y | 90.44% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -161.11% | Gross Margin | 86.55% | Volatility(W/M) | 4.01% 4.19% | Perf 5Y | -19.07% |
| Dividend TTM | - | EV/Sales | 17.12 | Sales Y/Y TTM | 140.58% | Oper. Margin | -466.78% | ATR (14) | 1.48 | Perf 10Y | -21.26% |
| Dividend Ex-Date | - | Quick Ratio | 9.79 | EPS Q/Q | 12.45% | Profit Margin | -418.24% | RSI (14) | 69.29 | Recom | 1.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.22 | Sales Q/Q | 259.25% | SMA20 | 13.62% ($33.47) | Beta | 0.64 | Target Price | $45.88 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/11/5 | SMA50 | 13.29% ($33.57) | Rel Volume | 0.67 | Prev Close | $36.85 |
| Employees | 540 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -2.13% 69.52% | SMA200 | 20.38% ($31.59) | Avg Volume(3M) | 1.10M | Price | $38.03 |
| IPO | 2013/7/24 | Option/Short | Yes/Yes | Trades | 6860 | Volume | 738,801 | Change | 3.2% |
🧬 This is a US biotech company that develops and commercializes treatments for rare blood disorders. It has commercialized an oral therapy that works by targeting metabolic enzymes to treat rare anemias and other blood conditions, and is expanding its indications to include beta-thalassemia and sickle cell disease. It is a rare blood disease biotech that combines the growth of prescriptions for its commercial product with an indication-expansion pipeline.
Over the past 1 year, roughly in the middle
17% below its 1-year high.
Traded less than usual. That is 67% of its average volume.
Next earnings report: November 5
9 days to go.
AGIO has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +19.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,309. Peers typically go for $1,648. Compared with its own 1-year average, it is 21% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -19.1%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 116.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #89 of 594 in the industry
Based on market cap of $2B.
RCUS#86 Arcus Biosciences Inc $2B PER - 
BHVN#87 Biohaven Ltd $2B PER - 
AUPH#88 Aurinia Pharmaceuticals Inc $2B PER 7.5 AGIO#89 Agios Pharmaceuticals Inc $2B PER - 
PHVS#90 Pharvaris NV $2B PER - 
FAQ
What kind of company is AGIO?
AGIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AGIO?
The market cap of AGIO is approximately $2.3B, ranking 1,960 within its sector.
What is the 52-week high and low for AGIO?
AGIO has recorded a 52-week high of $46.00 and a low of $22.24.
